An Expanded Access Program in pediatric patient with ENPP1 Deficiency treated with INZ-701
Latest Information Update: 21 May 2025
At a glance
- Drugs INZ-701 (Primary)
- Indications Calcinosis
- Focus Expanded access; Therapeutic Use
Most Recent Events
- 14 May 2025 According to an Inozyme Pharma media release, company today updated observations on ADAs from Expanded Access Program (EAP).
- 21 Feb 2025 According to a Inozyme Pharma media release, the data from this study will be presented at the CHOP Cardiology Annual Meeting, held February 19-23, 2025, in Orlando, Florida.
- 28 Mar 2023 New trial record